Cost-effectiveness of Tumor-treating Fields Added to Maintenance Temozolomide in Patients with Glioblastoma: an Updated Evaluation Using a Partitioned Survival Model

Overview

Journal J Neurooncol

Publisher Springer

Date 2019 May 26

PMID 31127507

Citations 15

Authors

Martin Connock

Peter Auguste

Claude Dussart

Jacques Guyotat

Xavier Armoiry

Affiliations

Soon will be listed here.

Abstract

Purpose: A first cost-effectiveness analysis has raised a strong concern regarding the cost of tumor treatment fields (TTF) added to maintenance temozolomide for patients with glioblastoma. This evaluation was based on effectiveness outcomes from an interim analysis of the pivotal trial, moreover it used a "standard" Markov model. Our objective was to update the cost-effectiveness evaluation using the more flexible potential of the "partitioned survival" model design and using the latest effectiveness data.

Methods: We developed the model with three mutually exclusive health states: stable disease, progressive disease, and dead. Good fit parametric models were developed for overall survival and progression free survival and these generated clinically plausible extrapolations beyond the observed data. We adopted the perspective of the French national health insurance and used a 20-year time horizon. Results were expressed as cost/life-years (LY) gained (LYG).

Results: The base case model generated incremental benefit of 0.604 LY at a cost of €453,848 which, after 4% annual discounting of benefits and costs, yielded an incremental cost effectiveness ratio (ICER) of €510,273/LYG. Using sensitivity analyses and bootstrapping methods results were found to be relatively robust and were only sensitive to TTF device costs and the modelling of overall survival. To achieve an ICER below €100,000/LYG would require a reduction in TTF device cost of approximately 85%.

Conclusions: Using a different type of model and updated survival outcomes, our results show TTF remains an intervention that is not cost-effective, which greatly restrains its diffusion to potentially eligible patients.

Citing Articles

Metastatic brain tumors: from development to cutting-edge treatment.

Tanzhu G, Chen L, Ning J, Xue W, Wang C, Xiao G MedComm (2020). 2024; 6(1):e70020.

PMID: 39712454 PMC: 11661909. DOI: 10.1002/mco2.70020.

Cost-effectiveness analysis of Tumor Treating Fields treatment in Chinese patients with metastatic non-small cell lung cancer.

Pei Z, Xiao N, Yang P Front Public Health. 2024; 12:1276049.

PMID: 39502829 PMC: 11534589. DOI: 10.3389/fpubh.2024.1276049.

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.

Khagi S, Kotecha R, Gatson N, Jeyapalan S, Abdullah H, Avgeropoulos N Oncologist. 2024; 30(2).

PMID: 39401002 PMC: 11883162. DOI: 10.1093/oncolo/oyae227.

Cost of medical care for malignant brain tumors at hospitals in the Japan Clinical Oncology Group brain-tumor study group.

Motomura K, Sasaki K, Sugii N, Yamaguchi S, Inoue H, Oshima A Jpn J Clin Oncol. 2024; 54(10):1123-1131.

PMID: 39223700 PMC: 11456849. DOI: 10.1093/jjco/hyae116.

Combination tumor-treating fields treatment for patients with metastatic non-small cell lung cancer: A cost-effectiveness analysis.

Liu K, Zhu Y, Zhu H, Zeng M Cancer Med. 2024; 13(5):e7070.

PMID: 38468503 PMC: 10928449. DOI: 10.1002/cam4.7070.

References

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S . The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007; 11(45):iii-iv, ix-221. DOI: 10.3310/hta11450. View

Guyot P, Ades A, Ouwens M, Welton N . Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12:9. PMC: 3313891. DOI: 10.1186/1471-2288-12-9. View

Kovic B, Xie F . Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015; 33(20):2296-302. DOI: 10.1200/JCO.2014.59.7245. View

Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O . Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol. 2010; 12(7):725-35. PMC: 2940657. DOI: 10.1093/neuonc/noq030. View

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

Lamers L, Stupp R, van den Bent M, Al M, Gorlia T, Wasserfallen J . Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study. Cancer. 2008; 112(6):1337-44. DOI: 10.1002/cncr.23297. View

Guzauskas G, Salzberg M, Wang B . Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. CNS Oncol. 2018; 7(3):CNS23. PMC: 6200060. DOI: 10.2217/cns-2018-0010. View

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B . Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23):2306-2316. PMC: 5820703. DOI: 10.1001/jama.2017.18718. View

Seiz M, Krafft U, Freyschlag C, Weiss C, Schmieder K, Lohr F . Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol. 2010; 136(11):1691-5. DOI: 10.1007/s00432-010-0827-6. View

10.

Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X . The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016; 18(8):1129-36. PMC: 4933490. DOI: 10.1093/neuonc/now102. View

11.

Porter K, McCarthy B, Berbaum M, Davis F . Conditional survival of all primary brain tumor patients by age, behavior, and histology. Neuroepidemiology. 2011; 36(4):230-9. PMC: 3665939. DOI: 10.1159/000327752. View

12.

Wu B, Miao Y, Bai Y, Ye M, Xu Y, Chen H . Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One. 2012; 7(4):e34588. PMC: 3325281. DOI: 10.1371/journal.pone.0034588. View

13.

Guzauskas G, Pollom E, Stieber V, Wang B, Garrison Jr L . Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. J Med Econ. 2019; 22(10):1006-1013. DOI: 10.1080/13696998.2019.1614933. View

14.

Waschke A, Arefian H, Walter J, Hartmann M, Maschmann J, Kalff R . Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. J Neurooncol. 2018; 138(2):359-367. DOI: 10.1007/s11060-018-2804-x. View

15.

Messali A, Hay J, Villacorta R . The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol. 2013; 15(11):1532-42. PMC: 3813411. DOI: 10.1093/neuonc/not096. View

16.

Gilbert M, Dignam J, Armstrong T, Wefel J, Blumenthal D, Vogelbaum M . A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8):699-708. PMC: 4201043. DOI: 10.1056/NEJMoa1308573. View

17.

Stupp R, Brada M, van den Bent M, Tonn J, Pentheroudakis G . High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3:iii93-101. DOI: 10.1093/annonc/mdu050. View

18.

Stupp R, Taillibert S, Kanner A, Kesari S, Steinberg D, Toms S . Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015; 314(23):2535-43. DOI: 10.1001/jama.2015.16669. View

19.

Williams C, Lewsey J, Mackay D, Briggs A . Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling. Med Decis Making. 2016; 37(4):427-439. PMC: 5424853. DOI: 10.1177/0272989X16670617. View

20.

Preusser M, Lim M, Hafler D, Reardon D, Sampson J . Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol. 2015; 11(9):504-14. PMC: 4782584. DOI: 10.1038/nrneurol.2015.139. View